Home / Healthcare / UCB S.A. - Product Pipeline Review - 2015

UCB S.A. - Product Pipeline Review - 2015

Published: Apr 2015 | No Of Pages: 90 | Published By: Global Markets Direct

UCB S.A. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'UCB S.A. - Product Pipeline Review - 2015', provides an overview of the UCB S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of UCB S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of UCB S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of UCB S.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the UCB S.A.'s pipeline products

Reasons to buy

- Evaluate UCB S.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of UCB S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the UCB S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of UCB S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of UCB S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of UCB S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
UCB S.A. Snapshot 6
UCB S.A. Overview 6
Key Information 6
Key Facts 6
UCB S.A. - Research and Development Overview 7
Key Therapeutic Areas 7
UCB S.A. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
UCB S.A. - Pipeline Products Glance 16
UCB S.A. - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
UCB S.A. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
UCB S.A. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
UCB S.A. - Drug Profiles 22
brivaracetam 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
certolizumab pegol 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
levetiracetam 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
epratuzumab 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lacosamide 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
rotigotine 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
bimekizumab 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
dapirolizumab pegol 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
UCB-0942 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
UCB-5857 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
UCB-7665 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Antibodies for Cancer, Immunology and Inflammation 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Recombinant Protein to Inhibit TNF-Alpha for Alzheimer's Disease 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
VR-942 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Antibodies for Diabetes and Metabolic Disorders 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Antibody to Inhibit Transglutaminase 2 for Fibrosis 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
UCB S.A. - Pipeline Analysis 58
UCB S.A. - Pipeline Products by Target 58
UCB S.A. - Pipeline Products by Route of Administration 60
UCB S.A. - Pipeline Products by Molecule Type 61
UCB S.A. - Pipeline Products by Mechanism of Action 62
UCB S.A. - Recent Pipeline Updates 63
UCB S.A. - Dormant Projects 79
UCB S.A. - Discontinued Pipeline Products 80
Discontinued Pipeline Product Profiles 80
CDP-323 80
CDP-435 80
CDP-484 81
CDP-860 81
lacosamide 81
seletracetam 81
UCB-2892 81
WX-037 82
WX-554 82
UCB S.A. - Company Statement 83
UCB S.A. - Locations And Subsidiaries 84
Head Office 84
Other Locations & Subsidiaries 84
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

UCB S.A., Key Information 6
UCB S.A., Key Facts 6
UCB S.A. - Pipeline by Indication, 2015 9
UCB S.A. - Pipeline by Stage of Development, 2015 10
UCB S.A. - Monotherapy Products in Pipeline, 2015 11
UCB S.A. - Partnered Products in Pipeline, 2015 12
UCB S.A. - Partnered Products/ Combination Treatment Modalities, 2015 13
UCB S.A. - Out-Licensed Products in Pipeline, 2015 14
UCB S.A. - Out-Licensed Products/ Combination Treatment Modalities, 2015 15
UCB S.A. - Pre-Registration, 2015 16
UCB S.A. - Phase III, 2015 17
UCB S.A. - Phase II, 2015 18
UCB S.A. - Phase I, 2015 19
UCB S.A. - Preclinical, 2015 20
UCB S.A. - Discovery, 2015 21
UCB S.A. - Pipeline by Target, 2015 59
UCB S.A. - Pipeline by Route of Administration, 2015 60
UCB S.A. - Pipeline by Molecule Type, 2015 61
UCB S.A. - Pipeline Products by Mechanism of Action, 2015 62
UCB S.A. - Recent Pipeline Updates, 2015 63
UCB S.A. - Dormant Developmental Projects,2015 79
UCB S.A. - Discontinued Pipeline Products, 2015 80
UCB S.A., Subsidiaries 84

UCB S.A. - Pipeline by Top 10 Indication, 2015 8
UCB S.A. - Pipeline by Stage of Development, 2015 10
UCB S.A. - Monotherapy Products in Pipeline, 2015 11
UCB S.A. - Partnered Products in Pipeline, 2015 12
UCB S.A. - Out-Licensed Products in Pipeline, 2015 14
UCB S.A. - Pipeline by Top 10 Target, 2015 58
UCB S.A. - Pipeline by Top 10 Route of Administration, 2015 60
UCB S.A. - Pipeline by Top 10 Molecule Type, 2015 61
UCB S.A. - Pipeline Products by Top 10 Mechanism of Action, 2015 62

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +